The data listed in Table 4 and Fig. 22 demonstrate that compound 16c has the strongest inhibitory effect among the tested compounds against to tropomyosin receptor kinase A (TrKA) with IC50 = 0.047 ± 0.0027 μg/ml compared to Larotrectinib with IC50 = 0.034 ± 0.0021 μg/ml using the HepG2 cancer cell line. This evidence concerns the gene NTRK1 and cancer.